Treatment using arachidonic acid metabolite and particulate form

Details Treatment using arachidonic acid metabolite and particulate form Treatment using arachidonic acid metabolite and particulate form

1995-01-11

1998-11-24

Kishore, Gollamudi S.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

424501, 514573, A61K 9127, A61K 916, A61K 31557

Patent

active

058403280

ABSTRACT:
A composition comprises a free arachidonic acid metabolite and endocystosable particles such as phagocytosable or opsonizable particles, or particles binding to phagocytic receptors to serum proteins, and the like. The composition, in the form of a therapeutic formulation may be administered alone, or with other bioactive agents, for the treatment of a disorder characterized by cell activation/adhesion, inflammation or toxemia. A second method of treating such disorders comprises the administration of an endocytosable particle.

REFERENCES:
patent: 4411894 (1983-10-01), Schrank
patent: 4493847 (1985-01-01), Mizishuma et al.
patent: 4522803 (1985-06-01), Lenk et al.
patent: 4544545 (1985-10-01), Ryan
patent: 4588578 (1986-05-01), Fountain et al.
patent: 4619794 (1986-10-01), Hauser
patent: 4684633 (1987-08-01), Imagawa et al.
patent: 4820732 (1989-04-01), Shell et al.
patent: 4955878 (1990-09-01), See et al.
patent: 4975282 (1990-12-01), Cullis et al.
patent: 5008050 (1991-04-01), Cullis et al.
patent: 5030453 (1991-07-01), Lenk et al.
patent: 5049390 (1991-09-01), Wodjan
patent: 5059421 (1991-10-01), Loughrey et al.
patent: 5082664 (1992-01-01), Lenk et al.
patent: 5169637 (1992-12-01), Lenk et al.
patent: 5262168 (1993-11-01), Lenk et al.
Ejerman et al., "Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia", Proc. Natl. Acad. Sci. USA, vol. 92, pp. 2815-2819 (Mar. 1995).
Bangham et al., "Diffusion of univalent ions across the lamellae of swollen phospholipids", J. Mol. Biol, 13: 238-252 (1965).
Cullis, et al., Liposomes, From Biophysics to Therapeutics (M. Ostro, ed.), Marcel Dekker (New York), 1987, pp. 39-72.
Darnell, et al., Moleculare Cell Biology, Scientific American Books, Inc., New York, 1986, pp. 638-644.
Fallman, et al., "Signaling Properties of CR3 (CD11b/CD18) and CR1 (CD35) in Relation to Phagocytosis of Complement-Psonized Particles", J. Immunology 151(1):330-338, 1993.
Goodman Gilman' The Pharmcological Basis of Therapeutics, Pergomon Press, New York 1990, pp. 600-611.
Hoshi, et al., "Prostaglandin E, incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy", Drugs Exptl. Clin. Res. 12(8):681, 1986.
Mizishuma, et al., "A multicenter double blind controlled study of lipo-pge1, gpge1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders", J.Rheumatol. 14:97 (1987).
Seewaldt-Becker et al., "Effect of Anti-Adhesive Antibodies on Repefusion Injury", (Sringer et al., eds.) in: Leukocyte Adhesion Molecules, Springer-Verlag, New York 1990, pp. 138-148.
Adhesion in Disease and Therapy, Springer, et al., eds, in: Leukocyte Adhesion Molecules, Springer-Verlag, New York, (1990) pp. 85-156.
Stedman's Medical Distionary (Illustraed((24th ed., J. V. Basmajian, et al., eds.,) Williams and Wilkins, Baltimore MD 1982, pp. 123-124, 707-708, 1274-1275 and 1464.
Stryer, Biochemistry 2nd ed., w. H. Freeman and Co., New York 1981, pp. 853-854.
Tate, et al., "Suppression of Acute Inflammation by 15 Methyl Prostaglandin E.sub.1," Laboratory Investigation 59(2):192-199 (1988).
Mizushina (1986) Drugs Exptl. Clin. Res. X11(8) 681.
Mizushina (1987) J Rheumatol. 14, 97 (1987).

Affiliated with

Also associated with

Rating

Treatment using arachidonic acid metabolite and particulate form does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment using arachidonic acid metabolite and particulate form, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment using arachidonic acid metabolite and particulate form will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1699376